What the trial was testing
The trial enrolled 46 patients with muscular dystrophy. The study was sponsored by ReveraGen BioPharma, Inc. and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
Boys on vamorolone grew normally while maintaining muscle strength, unlike standard steroid treatment which slows growth.
JAMA network open · 2022 · NCT03038399
These findings — that boys maintained their height percentiles instead of falling behind in growth — were published in the JAMA network open and represent the headline result of the study.
Researchers tracked outcomes across 46 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with muscular dystrophy, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
Vamorolone received FDA approval in 2023 for Duchenne muscular dystrophy in patients 2 years and older. It works similarly to standard steroids for maintaining muscle function but doesn't slow down growth like traditional steroids do. Talk to your child's doctor about whether vamorolone might be right for your family.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open muscular dystrophy trials
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia
The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with their thoughts.
A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy
This is a prospective observational study conducted to evaluate safety, tolerability, and functional outcomes of patients with DMD newly initiating oral givinostat or having started therapy within 6 months as part of routine clinical care in the US. The study has a planned maximum duration of 5 years for the first enrolled patients, including a 24-month enrollment period and a minimum of 2 years of follow-up.